Pharmaron Beijing Co Ltd Cash Flow Conversion Efficiency
Pharmaron Beijing Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Pharmaron Beijing Co Ltd (300759) has a cash flow conversion efficiency ratio of 0.068x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥1.04 Billion ≈ $151.79 Million USD) by net assets (CN¥15.18 Billion ≈ $2.22 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pharmaron Beijing Co Ltd (2014–2024)
Cash flow conversion efficiency of Pharmaron Beijing Co Ltd from 2014 to 2024. This chart illustrates how Pharmaron Beijing Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Pharmaron Beijing Co Ltd stock price today for real-time trading data and today's change.
Pharmaron Beijing Co Ltd Cash Flow Conversion Ratio Explained
Pharmaron Beijing Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pharmaron Beijing Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharmaron Beijing Co Ltd ranked by their cash flow conversion efficiency. Also see market cap of Pharmaron Beijing Co Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vietnam JSCmmercial Bank for Industry and Trade
VN:CTG
|
-0.013x |
|
Range Resources Corp
NYSE:RRC
|
0.050x |
|
Banco Santander (Brasil) S.A.
SA:SANB3
|
0.200x |
|
Jefferies Financial Group Inc
NYSE:JEF
|
0.151x |
|
Interpublic Group of Companies Inc
NYSE:IPG
|
0.049x |
|
GameStop Corp.
NYSE:GME
|
0.010x |
|
U-Haul Holding Company
NYSE:UHAL-B
|
0.091x |
|
ORKLA ADR/1 NK 625
F:OKL0
|
0.071x |
Annual Cash Flow Conversion Efficiency for Pharmaron Beijing Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Pharmaron Beijing Co Ltd from 2014 to 2024. Review Pharmaron Beijing Co Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥14.22 Billion ≈ $2.08 Billion |
CN¥2.58 Billion ≈ $377.05 Million |
0.181x | -12.90% |
| 2023-12-31 | CN¥13.24 Billion ≈ $1.94 Billion |
CN¥2.75 Billion ≈ $402.93 Million |
0.208x | +5.22% |
| 2022-12-31 | CN¥10.84 Billion ≈ $1.59 Billion |
CN¥2.14 Billion ≈ $313.56 Million |
0.198x | -1.11% |
| 2021-12-31 | CN¥10.30 Billion ≈ $1.51 Billion |
CN¥2.06 Billion ≈ $301.16 Million |
0.200x | +8.33% |
| 2020-12-31 | CN¥8.93 Billion ≈ $1.31 Billion |
CN¥1.65 Billion ≈ $241.24 Million |
0.185x | +54.10% |
| 2019-12-31 | CN¥7.84 Billion ≈ $1.15 Billion |
CN¥938.59 Million ≈ $137.34 Million |
0.120x | -61.96% |
| 2018-12-31 | CN¥2.34 Billion ≈ $342.70 Million |
CN¥737.26 Million ≈ $107.88 Million |
0.315x | +14.60% |
| 2017-12-31 | CN¥2.01 Billion ≈ $294.17 Million |
CN¥552.22 Million ≈ $80.81 Million |
0.275x | +105.46% |
| 2016-12-31 | CN¥1.76 Billion ≈ $258.04 Million |
CN¥235.77 Million ≈ $34.50 Million |
0.134x | -89.62% |
| 2015-12-31 | CN¥168.43 Million ≈ $24.65 Million |
CN¥216.94 Million ≈ $31.75 Million |
1.288x | +2641.07% |
| 2014-12-31 | CN¥258.25 Million ≈ $37.79 Million |
CN¥12.13 Million ≈ $1.78 Million |
0.047x | -- |
About Pharmaron Beijing Co Ltd
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more